Quick Answer
Atara Biotherapeutics, Inc. reported Stockholders Equity of -$38.50 million for fiscal year 2025.
Atara Biotherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$38.50M | +60.4% |
| 2024 | -$97.28M | -198.0% |
| 2023 | $99.23M | -21.6% |
| 2022 | $126.64M | -54.7% |
| 2021 | $279.61M | -39.5% |
| 2020 | $462.34M | +59.0% |
| 2019 | $290.78M | -14.3% |
| 2018 | $339.22M | +90.7% |
| 2017 | $177.86M | -29.9% |
| 2016 | $253.74M | -19.5% |
| 2015 | $315.10M | +205.4% |
| 2014 | $103.18M | +1036.6% |
| 2013 | -$11.02M | -195.6% |
| 2012 | -$3.73M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.63M | +59.5% | -4.5% |
| June 30, 2025 | -$35.04M | +68.4% | +36.4% |
| March 31, 2025 | -$55.07M | +44.0% | +43.4% |
| December 31, 2024 | -$97.28M | +2.0% | -7.4% |
| September 30, 2024 | -$90.54M | -78.1% | +18.3% |
| June 30, 2024 | -$110.87M | -1587.4% | -12.8% |
| March 31, 2024 | -$98.31M | -251.3% | +0.9% |
| December 31, 2023 | -$99.23M | -178.4% | -95.2% |
- Atara Biotherapeutics, Inc. showed an increase of +60.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, Atara Biotherapeutics, Inc.’s stockholders equity has declined by 933.1% (from -$3.73 million to -$38.50 million).
- The most recent figure is from Atara Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: